Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00256698 · OUTCOME

Percentage of Clinical Benefit Rate (CBR) Responders

Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy · Source last updated 2012-08-01

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
Not reported
Time frame
RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009

What was measured

No. of patients who were clinical benefit responders over the no. of randomised patients x100. A clinical benefit responder = a patient whose best response is CR, PR or SD\>=24 weeks (where a best response of SD = no new lesions and for existing lesions; neither suffient shrinkage to count as PR nor sufficient growth to count as progression)

Groups in this outcome

Fulvestrant + Anastrozole

Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg

Anastrozole

Anastrozole 1 mg

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Fulvestrant + Anastrozole258
Anastrozole256

Reported measurements

Source class 1
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Fulvestrant + Anastrozole55.0Not reportedNot reportedNot reportedNot reported
Anastrozole55.1Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        55.0
      2. group Id
        OG001
        value
        55.1
denoms
  1. counts
    1. group Id
      OG000
      value
      258
    2. group Id
      OG001
      value
      256
    units
    Participants
description
No. of patients who were clinical benefit responders over the no. of randomised patients x100. A clinical benefit responder = a patient whose best response is CR, PR or SD\>=24 weeks (where a best response of SD = no new lesions and for existing lesions; neither suffient shrinkage to count as PR nor sufficient growth to count as progression)
groups
  1. description
    Fulvestrant 250 mg Loading Dose Regimen + Anastrozole 1 mg
    id
    OG000
    title
    Fulvestrant + Anastrozole
  2. description
    Anastrozole 1 mg
    id
    OG001
    title
    Anastrozole
param Type
NUMBER
reporting Status
POSTED
time Frame
RECIST tumour assessments carried out every 8 weeks from randomisation until data cut-off on 30th April 2009
title
Percentage of Clinical Benefit Rate (CBR) Responders
type
SECONDARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice